Document is current
Any future updates will be listed below
-
Authors
Bell, Kirstine J.
Saad, Sonia
Tillett, Bree J.
McGuire, Helen M.
Bordbar, Sara
Yap, Yu Anne
Nguyen, Long T.
Wilkins, Marc R.
Corley, Susan
Brodie, Shannon
Duong, Sussan
Wright, Courtney J.
Twigg, Stephen
de St Groth, Barbara Fazekas
Harrison, Leonard C.
Mackay, Charles R.
Gurzov, Esteban N.
Hamilton-Williams, Emma E.
Mariño, Eliana https://orcid.org/0000-0001-5371-8778
-
Funding
Funding for this research was provided by:
Juvenile Diabetes Research Foundation Australia (2‐SRA‐2019‐703‐M‐B)
Juvenile Diabetes Research Foundation International (3-SRA-2019-730-S-B, (5-CDA-2019-758-A-N)
- License Information
-
More Information
Article History
Received: 28 October 2021
Accepted: 4 November 2021
First Online: 19 January 2022
Declarations
:
: The trial protocol was approved by the Sydney Local Health District Human Research Ethics Committee (HREC) (HREC/18/RPAH/241) and Monash University HREC. Clinical investigation of HAMSAB intervention was approved by Therapeutic Goods Administration (TGA) (CT-2020-CTN00691-1 v1). All patients provided written informed consent. The trial was registered with Australia New Zealand Clinical Trials Registry (ACTRN12618001391268).
: Not applicable.
: The authors declare no competing interests.
